Trilaciclib, an intravenous CDK 4/6 inhibitor, in combination with Hycamtin may reduce chemotherapy-induced myelosuppression in small cell lung cancer, according to one expert.
Dr. Lowell Hart
Advertisement
Articles by Dr. Lowell Hart
Advertisement
Latest Updated Articles
Addition of Trilaciclib May Mitigate Myelosuppression in Patients With Small Cell Lung CancerPublished: June 28th 2019 | Updated:
Advertisement
Advertisement
